

This listing of claims will replace all prior versions, and listings, of claims in the Application:

LISTING OF CLAIMS:

Claim 1 (previously presented): A method for determining a genotype associated with increased resistance to familial bipolar affective disorder in a family affected by bipolar affective disorder, comprising:

determining the genotype of at least one family member, wherein the genotype is determined with at least one marker for at least one chromosomal region linked to a locus associated with resistance to bipolar affective disorder, wherein the chromosomal regions are inclusive of and localized between *D4S402* and *D4S424*; inclusive of and localized between *D4S431* and *D4S404*; or inclusive and localized between *D11S394* and *D11S29*;

determining, after the age of onset, the bipolar affective disorder disease status in the family member;

comparing the genotype with the bipolar affective disorder disease status; and

determining therefrom the genotype associated with increased resistance to bipolar affective disorder.

Claim 2 (original): The method of claim 1, wherein the genotype is determined with markers for at least two of the chromosomal regions.

Claim 3 (original): The method of claim 2, wherein the genotype is determined with markers for three of the chromosomal regions.

Claim 4 (original): The method of claim 1, wherein the chromosomal region is inclusive of and localized between markers *D4S422* and *D4S1625*.

Claim 5 (original): The method of claim 4, wherein the marker is *D4S175*, *D4S422*, *D4S1576*, *D4S2294*, *D4S1579*, *D4S397*, *D4S3089*, *D4S2965*, *D4S192*, *D4S420*, *D4S1644*, *D4S3334*, or combinations thereof.

Claim 6 (original): The method of claim 1, wherein the chromosomal region is inclusive of and localized between markers *D4S3007* and *D4S419*.

Claim 7 (original): The method of claim 6, wherein the marker is *D4S3007*, *D4S394*, *D4S2983*, *D4S2923*, *D4S615*, *AFM_qJ84za9*, *D4S2928*, *D4S1065*, *D4S1582*, *D4S107*,

D4S3009, D4S2906, D4S2949, AFM087zg5, D4S2944, D4S403, D4S2942, D4S2984, D4S1602, D4S1511, D4S2311, D4S3048, or combinations thereof.

Claim 8 (original): The method of claim 7, wherein the marker is *D4S3009, D4S2906, D4S2949, AFM087zg5, D4S2944, D4S403, D4S2942, D4S2984, D4S1602, D4S1511, D4S2311, or combinations thereof.*

Claim 9 (original): The method of claim 1, wherein the chromosomal region is inclusive of and localized between markers *D11S133* and *D11S29*.

Claim 10 (original): The method of claim 9, wherein the marker is *D11S133, D11S147, CD3D, D11S285, D11S29, or combinations thereof.*

Claim 11 (original): The method of claim 1, wherein the genotype at a single chromosomal region is determined with at least three markers.

Claim 12 (original): The method of claim 1, wherein the marker is for a restriction fragment length polymorphism or microsatellite polymorphism.

Claim 13 (withdrawn)

Claim 14 (withdrawn)

Claim 15 (original): The method of claim 1, wherein the marker is amplified.

Claim 16 (original): The method of claim 15, wherein the marker is amplified by the polymerase chain reaction.

Claim 17 (original): The method of claim 1, wherein the presence or absence of an allele associated with increased resistance to bipolar affective disorder is determined.

Claim 18 (original): The method of claim 1, wherein the genotype of an affected family member is determined.

Claim 19 (original): The method of claim 1, wherein the genotype of a non-affected family member is determined.

Claim 20 (original): The method of claim 1, further comprising:

determining the genotype of at least one family member, wherein the genotype is determined with at least one marker for at least one chromosomal region linked to a locus associated with susceptibility to bipolar affective disorder, wherein the chromosomal regions are inclusive of and localized between *D6S344* and *D6S89*; inclusive of and localized between *D13S171* and *D13S218*; or at about *D15S148*.

Claim 21 (previously presented): The method of claim 1, further comprising:

determining the genotype of a tested individual from the affected family, wherein the genotype is determined with at least one marker for at least one chromosomal region linked to a locus associated with resistance to bipolar affective disorder, wherein the chromosomal regions are inclusive of and localized between *D4S402* and *D4S424*; inclusive of and localized between *D4S431* and *D4S404*; or inclusive and localized between *D11S133* and *D11S29*;

comparing the genotype of the tested individual to the genotype associated with increased resistance to bipolar affective disorder; and

determining therefrom the decreased risk of the tested individual developing familial bipolar affective disorder.

Claim 22 (original): The method of claim 21, wherein the genotype of the tested individual is compared to the genotype of an affected family member.

Claim 23 (previously presented): A method for determining the contribution of a chromosomal region to the presence of resistance to bipolar affective disorder in a family affected by bipolar affective disorder, comprising:

determining the corresponding genotype of at least two family members, wherein the genotype is determined with at least one marker for at least one tested chromosomal region linked to a locus associated with resistance to bipolar affective disorder, wherein the tested chromosomal regions are inclusive of and localized between *D4S402* and *D4S424*; inclusive of and localized between *D4S431* and *D4S404*; or inclusive and localized between *D11S133* and *D11S29*;

determining, after the age of onset, the bipolar affective disorder disease status in the family members;

comparing the genotypes of the family members; and

determining therefrom the contribution of the chromosomal region to the presence of resistance to bipolar affective disorder in the family.

Claim 24 (previously presented): A method for determining a genotype associated with increased susceptibility to familial bipolar affective disorder in a family affected by bipolar affective disorder, comprising:

determining the genotype of at least one family member, wherein the genotype is determined with at least one marker for at least one chromosomal region linked to a locus associated with susceptibility to bipolar affective disorder, wherein the chromosomal regions are inclusive of and localized between *D6S344* and *D6S89*; inclusive of and localized between *D13S171* and *D13S218*; or at about *D15S148*;

determining, after the age of onset, the bipolar affective disorder disease status in the family member;

comparing the genotype with the bipolar affective disorder disease status; and

determining therefrom the genotype associated with increased susceptibility to bipolar affective disorder.

Claim 25 (original): The method of claim 24, wherein the marker associated with susceptibility is *D6S7*, *D13S1*, *D15S45*, or combinations thereof.

Claim 26 (previously presented): The method of claim 24, further comprising:

determining the genotype of a tested individual from the affected family, wherein the genotype is determined with at least one marker for at least one chromosomal region linked to a locus associated with resistance to bipolar affective disorder, wherein the chromosomal regions are inclusive of and localized between *D4S402* and *D4S424*; inclusive of and localized between *D4S431* and *D4S404*; or inclusive and localized between *D11S133* and *D11S29*;

comparing the genotype of the tested individual to the genotype associated with increased susceptibility to bipolar affective disorder; and

determining therefrom the increased or decreased risk of the tested individual

developing familial bipolar affective disorder.

Claim 27 (withdrawn)